Clinical comparative observation and its pharmacoeconomic evaluation of moxifloxacin vs. cefoperazone sodium and tazobactam sodium on genitourinary infection / 中国医师进修杂志

ABSTRACT

Objective To compare the clinical efficacy of moxifloxacin vs.cefoperazone sodium/tazobactam sodium in the treatment of genitourinary infection,and provide a reference for clinical rational use of antimicrobial drugs through pharmacoeconomics studies.Methods A total of 115 cases with genitourinary infection were randomly divided into moxifloxacin group (59 cases) and cefoperazone sodium/tazobactam sodium group (cephalosporin group,56 cases) by random digits table method.Moxifloxacin group was treated with moxifloxacin hydrochloride tablets,cephalosporin group was given cefoperazone sodium/tazobactam sodium by intravenous infusion for 7 d.The clinical efficacy and incidence of adverse reaction was compared,and the two drugs were evaluated by pharmacoeconomic study.Results The clinical total effective rate in moxifloxacin group and cephalosporin group was respectively 86.4％ (51/59) and 85.7％(48/56),and bacteriological eradication rate was respectively 89.3％(67/75) and 88.9％(64/72),and the difference between the two groups was not statistically significant (P ＞ 0.05).The incremental cost-effectiveness ratios in moxifloxacin group and cephalosporin group were 2.29 and 21.56,and the difference was statistically significant (P ＜0.01).The incidence of adverse reactions in moxifloxacin group and cephalosporin group was 6.8％ (4/59),3.6％ (2/56),and there was no significant difference (P ＞ 0.05).Conclusion In the treatment of genitourinary infections,moxifloxacin and cefoperazone sodium/tazobactam sodium has equivalent efficacy,but moxifloxacin is good to reduce the cost of treatment and is easy to take,which is better treatment programs.